Shares of Givaudan SA (OTCMKTS:GVDNY – Get Free Report) have been given an average rating of “Hold” by the eight research firms that are presently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company.
GVDNY has been the topic of several analyst reports. Berenberg Bank downgraded Givaudan from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Deutsche Bank Aktiengesellschaft upgraded Givaudan from a “hold” rating to a “buy” rating in a report on Tuesday, June 9th. Barclays downgraded Givaudan from a “strong-buy” rating to a “hold” rating in a report on Friday, March 27th. Zacks Research upgraded Givaudan from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Finally, Kepler Capital Markets downgraded Givaudan from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 13th.
View Our Latest Stock Analysis on GVDNY
Givaudan Price Performance
About Givaudan
Givaudan is a Swiss-based global company that develops, manufactures and supplies flavors, fragrances and active cosmetic ingredients for a broad range of consumer products. The company’s core activities are organized around creating taste and scent solutions—ranging from fine fragrances and consumer-packaged goods scents to flavor systems for food and beverages and functional ingredients for personal care. Givaudan works with brand owners and manufacturers to design sensory experiences, improve product performance and meet formulation or regulatory requirements.
Its product and service offerings include bespoke fragrance creation, flavor formulation, natural ingredient sourcing, aroma chemicals, taste modulators and application support such as prototyping and sensory testing.
Recommended Stories
- Five stocks we like better than Givaudan
- 3 Retail Winners Using Cash Flow to Stay Ahead
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Receive News & Ratings for Givaudan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Givaudan and related companies with MarketBeat.com's FREE daily email newsletter.
